~~<i id='6A57DCC531'><strike id='6A57DCC531'><tt id='6A57DCC531'><pre id='6A57DCC531'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：comprehensive 2025-10-01 11:47:20 - browse：7469

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Lawmakers grill UnitedHealth CEO on Change cyberattack

explore

leisure time

hotspot

explore

entertainment

leisure time

MikeReddyforSTATIshouldbeirateanddespondentabouttheSupremeCourt’sscrappingofaffirmativeactioninadmis

WSS

What to expect as Trump is arraigned on his Jan 6. indictment

Brain technologies pose threats that are all too real, experts warn

Scientists inch closer to single

The creative science of coining drug names

AltruBio raises $225 million to develop ulcerative colitis drug

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

hotspot

comprehensive

explore

What does generative AI mean for health care? We asked experts

Adults seen as increasingly susceptible to measles

Walensky prepares to leave CDC — and Congress — behind

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Malaria cases in Florida and Texas: Here’s what you need to know

Crowdfunding for medical bills sidesteps core problem, author says

Supreme Court strikes down use of affirmative action

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Medicare details structure of new drug price negotiation program

The high personal cost of affirmative action for Black doctors

leisure time

Vertex non

As health system earnings go up, health insurance stocks go down

What the US credit downgrade means for the economy, your finances

PBM executives asked to testify by House panel

AltruBio raises $225 million to develop ulcerative colitis drug

Brain technologies pose threats that are all too real, experts warn

hotspot

explore

entertainment

leisure time